Opening testimony in the Elizabeth Holmes fraud trial paints a grim picture of Theranos’s financial situation. The company that once boasted having a valuation of $9 billion was not only losing millions, but for some years it didn’t produce any revenue while telling investors differently.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,